Pharvaris Email Format

Pharmaceutical ManufacturingZug, Switzerland51-200 Employees

Pharvaris is a mid-sized biopharmaceutical company based in Zug, Switzerland, focused on developing oral therapies for bradykinin-mediated diseases. Its core approach targets the bradykinin B2 receptor with oral antagonists intended for hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). By leveraging established science, the company seeks to provide new treatment options that address unmet medical needs and complement standard care. The organization operates within the pharmaceutical manufacturing sector and concentrates on late-stage clinical development in the field of rare diseases.

Pharvaris serves patients and clinicians managing bradykinin-mediated diseases, with late-stage programs that include plans for a potential deucrictibant IR launch and corresponding commercial readiness. Recent activity includes the announcement of clinical data presentations at the EAACI Annual Congress 2026 and ongoing enrollment in pivotal studies.

Sign up for free to view info

Company overview Employee directory